OncoMatch/Clinical Trials/NCT07249346

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Is NCT07249346 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ruxolitinib and Myeloablative conditioning regimen for leukemia.

Phase 2RecruitingHannah Choe, MDNCT07249346Data as of May 2026

Treatment: Ruxolitinib · Myeloablative conditioning regimen · Cyclophosphamide · Tacrolimus — This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC) allogeneic peripheral blood stem cell transplantation (PBSCT).

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Prior therapy

Must have received: myeloablative conditioning regimen — planned

Planned myeloablative (MAC) conditioning regimen

Cannot have received: allogeneic transplant

Prior allogeneic transplant

Cannot have received: ruxolitinib (ruxolitinib)

Prior use of ruxolitinib

Cannot have received: immune checkpoint inhibitor

Prior use of immune checkpoint inhibitors (i.e., PD1, PDL1, CTLA4 modulators) within six (6) months prior to conditioning

Lab requirements

Kidney function

Estimated creatinine clearance >60 ml/min (C-G formula)

Liver function

AST/ALT <3x ULN; Total bilirubin <2 mg/dL excluding Gilbert's syndrome or hemolysis

Cardiac function

Left ventricular ejection fraction at least 45%

Cardiac function: Left ventricular ejection fraction at least 45%; Estimated creatinine clearance greater than 60 ml/min (C-G formula); Liver function: AST/ALT <3x ULN; Total bilirubin <2 mg/dL excluding Gilbert's syndrome or hemolysis; There are no restrictions based on blood counts

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Ohio State University Comprehensive Cancer Center · Columbus, Ohio

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify